The makers of Euthyrox T4 tablets decided to reformulate and put outa paper justifying this as being accurate as regards bioequivalence, The article is as below. I know well that many posters on TUK complain about practical non-equivalence of reformulated tablets. We have submitted a Letter to the Editor regarding the best mathematical/statistical way of analysing this data. When the data is properly statstically handled, the comparison at the individual level shows far from a close relationship (almost random). This should help other reformulators to consider the optimum statistical analysis in producing their results. The obvious solution is to keep to one formulation by one producer if at all possible.
Curr Med Res Opin. 2017 Feb;33(2):169-174. doi: 10.1080/03007995.2016.1246434. Epub 2016 Oct 21.
New levothyroxine formulation meeting 95-105% specification over the whole shelf-life: results from two pharmacokinetic trials.